Finally, acquired mutations in the ATP-binding domain in tumor cells, such as Gatekeeper mutations in the kinase domain, may lead to decreased drug-binding affinity for PLK1 inhibitors and thus the phenomenon of acquired resistance (82). Here, PLK1 is linked to neoplasm.